Bispecific antibody targeting both IL-13 and OX-40L (Almirall)

N/A

Report date: 2026/05/20 20:02:01

Base Information

Drug NameBispecific antibody targeting both IL-13 and OX-40L (Almirall)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin-13 modulatorsTumor necrosis factor ligand superfamily member 4 modulators

TargetsInterleukin-13Tumor necrosis factor ligand superfamily member 4

Therapy Area/IndicationsDermatitis, Atopic

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAlmirall Sa

China Registration ClassN/A

Develop Information

Active CompaniesAlmirall Sa

Inactive CompaniesN/A

Active IndicationsDermatitis, Atopic

Inactive IndicationsN/A

Other Information

ATC CodeN/A